q&more
My watch list
my.chemie.de  
Login  

News

Research into Parkinson’s disease: binding-protein prevents fibril proliferation

HHU / Wolfgang Hoyer

Aggregation inhibitor beta-wrapin AS69 (grey) binds a region in the otherwise disordered Parkinson’s protein alpha-synuclein (orange), preventing elongation and formation of new protein fibrils (red)

04-Sep-2019: Several neurodegenerative diseases such as Parkinson’s are closely linked to the aggregation of a specific protein, α-synuclein. An international collaborative project involving Heinrich Heine University Düsseldorf (HHU), Forschungszentrum Jülich (FZJ) and RWTH Aachen University has now shed light on the mechanisms used by a specific binding-protein discovered by them to prevent aggregation. In the journal eLife, they also describe how the binding-protein improves symptoms of Parkinson’s disease in fruit flies.

Protein aggregates have been observed in the nerve tissue of patients with Parkinson’s disease which consist of individual components (monomers) of the protein α-synuclein which assemble into what are referred to as amyloid fibrils. Similar deposits are also found in the case of other neurodegenerative diseases such as Alzheimer’s. Researchers are looking for approaches to prevent fibril formation and potentially cure the diseases.

In 2014, Düsseldorf-based researchers led by Prof. Dr. Wolfgang Hoyer described how a class of engineered binding-proteins, β-wrapins, are able to prevent α-synuclein aggregation. Hoyer says: “We subsequently investigated with research partners precisely how the β-wrapins function and where they disrupt the α-synuclein aggregation process.”

The collaborative group including first author of the study Emil D. Agerschou and Prof. Hoyer from the Chair of Physical Biology at HHU and the FZJ, Prof. Dr. Alexander Büll (Technical University of Denmark) and Prof. Dr. Björn Falkenburger (Technical University of Dresden) as well as other partners at the University of Cambridge and the German Center for Neurodegenerative Diseases in Bonn has now presented its findings in the journal eLife.

Firstly, the researchers found out that the β-wrapins prevent new α-synuclein monomers from elongating the amyloid fibrils. To do this, the β-wrapins capture the monomers and form chemical complexes with them.
But there is a further property that makes the β-wrapins particularly effective, as explained by Emil Agerschou: “The β-wrapins prevent seed fibrils from forming in the first place. It is especially relevant that very small amounts of the wrapins are sufficient for this to happen, so you don’t need a binding-protein for every monomer.” This is referred to as a ‘sub-stoichiometric effect’ that makes the process especially effective. It is the aforementioned complexes comprising binding-proteins and monomers that are responsible for inhibiting seed formation.

“We discovered a few years ago that α-synuclein fibrils can proliferate quickly under certain conditions in a kind of chain reaction. We were really astonished to see that the β-wrapins suppress the chain reactions very efficiently”, adds Prof. Büll: “We think we now understand how this is achieved.”

In addition, the researchers have examined the effect of the β-wrapins not only in test tubes but also in cell culture and in animal models. Diseased fruit flies (Drosophila) treated with β-wrapins displayed notably improved motor skills in a climbing assay.

Prof. Hoyer is still cautious about potential therapeutic use: “The positive results in living creatures give us hope that we have possibly found a path to an active ingredient through the β-wrapins. However, it will still be a long time before this could potentially be used for humans.”

Original publication:
E. D. Agerschou, T. Saridaki, P. Flagmeier, C. Galvagnion, D. Komnig, L. Heid, V. Prasad, H. Shaykhalishahi, D. Willbold, C. M. Dobson, A. Voigt, B. H. Falkenburger, W. Hoyer, A. K. Buell; "An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils"; eLife; 2019;8:e46112

Facts, background information, dossiers

  • neurodegenerative diseases
  • Parkinson's disease
  • alpha-Synuclein
  • amyloid fibrils
  • fibrils
  • β-wrapins

More about Universität Düsseldorf

  • News

    Biological risk potential of nanoparticles studied

    Carbon nanoparticles are a promising tool for biomedical applications, for example for targeted transportation of biologically active compounds into cells. A team of researchers from the Physics, Medicine and Chemistry departments at Heinrich Heine University Düsseldorf (HHU) has now examin ... more

    Assemblies of proteins relevant not only for Alzheimer’s and Parkinson’s disease

    Amyloid fibrils play a crucial role in neurodegenerative illnesses. Scientists from Heinrich Heine University Düsseldorf (HHU) and Forschungszentrum Jülich have now been able to use cryo-electron microscopy (cryo-EM) to decode the spatial structure of the fibrils that are formed from PI3K S ... more

    New anti-malarial lead compound successfully tested

    Researchers in a team headed by Professor Thomas Kurz at the Institute of Pharmaceutical and Medicinal Chemistry of Heinrich Heine University Düsseldorf (HHU) have successfully tested an optimised lead compound in animal experiments that acts against plasmodia, i.e. malaria parasites. Lead ... more

  • q&more articles

    Surprisingly simple molecules as potential OLED-Emitters?

    Organic light emitting diodes (OLEDs) are presently conquering the market for displays of smartphones and TVs. They also have a great potential in lighting applications. Current devices for the blue part of the visible spectrum lag behind their green and red counterparts in terms of efficie ... more

  • Authors

    Kristoffer Thom

    Kristoffer Thom, born in 1993, studied chemistry at the Heinrich-Heine-University Düsseldorf, where he completed his bachelor thesis in the group of Rainer Weinkauf on mass spectrometry of peptides. For his master thesis he joined the group of Peter Gilch, investigating novel emitters for O ... more

    Prof. Dr. Peter Gilch

    Peter Gilch, born 1970, studied chemistry at the University of Konstanz before receiving his PhD in 1999 from the Technical University Munich. He then joined the Ludwig-Maximilians-University Munich for his Habilitation (2004) at the Lehrstuhl für BioMolekulare Optik. Since 2009 he has been ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE